# Immunizations

Whitney George

--- 

## Vaccines

<table>
  <tr>
    <th>Vaccine</th>
    <th>Indications</th>
  </tr>
  <tr>
    <td>COVID-19</td>
    <td>Recommended for all adults<br>Unvaccinated ➔ 1 dose of Moderna or Pfizer-BioNTech vaccine OR 2 dose series of updated Novavax at 0 then 3-8 weeks</td>
  </tr>
  <tr>
    <td>Influenza</td>
    <td>Recommended for all Adults: 1 dose annually</td>
  </tr>
  <tr>
    <td>Respiratory Syncytial Virus (RSV)</td>
    <td>Recommended for:<br>➔ 60+ years: consider based on shared clinical decision making giving 1 dose to those most at risk for severe RSV disease  (heart failure, over age 80, cardiopulmonary disease)<br>➔ Pregnant at 32-36 weeks gestation from Sept-January (most states)<br>*** NOT covered by Medicare in clinic***</td>
  </tr>
  <tr>
    <td>Tetanus, diphtheria, pertussis (Tdap or Td)</td>
    <td>Recommended for all adults: 1 dose Tdap, then Td or Tdap booster q10 years<br>➔ For patients with clean/minor wounds, administer only if >10 years since last tetanus containing vaccine<br>➔ For all other wounds, administer if >5 years since last tetanus containing vaccine<br>***NOT covered by Medicare in clinic***</td>
  </tr>
  <tr>
    <td>Measles, mumps, rubella (MMR)</td>
    <td>Usually given in childhood, recommended for all adults without evidence of immunity to measles, mumps or rubella (2 doses separated by at least 28 days)</td>
  </tr>
  <tr>
    <td>Varicella (VAR)</td>
    <td>Usually given in childhood, recommended for all adults without evidence of immunity to varicella - 2 dose series 4-8 weeks apart</td>
  </tr>
  <tr>
    <td>Zoster recombinant (RZV)</td>
    <td>Recommended for all adults 50+ years old: 2 dose series 2-6 months apart<br>***NOT covered by Medicare in clinic***</td>
  </tr>
  <tr>
    <td>Human Papillomavirus (HPV)</td>
    <td>Recommended for all adults 18-26 years old: 2 or three dose series depending on age at initial vaccine<br>➔ Age 9-14 yrs at initial vaccination and received 1 dose or 2 doses less than 5 months apart, give additional dose. If given between 9-14 and received two doses, at least 5 months apart – no additional dose<br>➔ Age 15 or older, three dose series at 0, 1-2 m, 6m<br>➔ Age 27–45 : shared clinical decision making on vaccination (3 dose series)</td>
  </tr>
  <tr>
    <td>Pneumococcal (PCV15, PCV20, PPSV23)</td>
    <td>Recommended for all adults 65+ years: depends on previously administered type of Pneumo vaccine, recommend CDC app (cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html)<br>➔ If no prior pneumococcal vaccines, can give one dose of PCV15 OR PCV20<br>➔ Immunization also recommended for adults 19-64 with immunocompromising conditions (renal failure, nephrotic syndrome, immunodeficiencies, iatrogenic immunosuppression, malignancy, HIV, Hodgkin disease, solid organ transplant, asplenia, SSD, alcoholism, chronic heart/liver/lung disease, tobacco use, diabetes)</td>
  </tr>
  <tr>
    <td>Hepatitis A</td>
    <td>Recommended for all adults who request vaccination OR is at risk<br>➔ At risk populations include patients with chronic liver disease, HIV infection, MSM, IVDU, persons experiencing homelessness, travel in countries with high/intermediate endemic risk, healthcare settings with high potential for exposure ➔2 dose (havrix 6-12 m apart) or 3 dose series (Twinrix Hep-A-HepB, 0,1, 6 m apart)</td>
  </tr>
  <tr>
    <td>Hepatitis B</td>
    <td>Recommended for:<br>➔ All adults aged 19-56 years: 2 (heplisav 4 wk apart), 3 (Engerix-B, PreHevbrio, or Recombinvax at 0,1, 6 m) or 4 dose series (hepA-HepB Twinrix accelerated schedule)<br>➔ 60+ years: may receive without risk factors, should receive with known risk factors or requests. Risk factors include: Chronic liver disease, HIV, sexual exposure risk, IVDU, Incarceration, travel to countries with high/intermediate endemic hep B Risk)</td>
  </tr>
  <tr>
    <td>Meningococcal A, C, W, Y (MenACWY)</td>
    <td>Recommended for:<br>➔ Patients with asplenia (anatomical or functional), including HIV, complement deficiencies, compliment inhibitor medication – 2 dose series (MenACWY) at least 8 weeks apart, revaccinated q5 yr if risk remains<br>➔ Patients traveling to countries with hyperendemic or epidemic meningococcal disease – 1 dose MenACWY and revaccinate q5yr if risk remains<br>➔ First-year college studies who live in residential housing or military recruits- 1 dose MenACWY</td>
  </tr>
  <tr>
    <td>Meningococcal B (MenB)</td>
    <td>Recommended for adults 16-23 years: based on shared clinical decision making, 2 dose series</td>
  </tr>
  <tr>
    <td>Haemophilus influenzae type b (Hib)</td>
    <td>Recommended for:<br>➔ Adults with anatomic or functional asplenia including sickle cell, and stem cell transplant recipients</td>
  </tr>
</table>
